A novel vaginal pH regulator: results from the phase 3 AMPOWER contraception clinical trial
01 June 2020
Primary efficacy and safety results from the Phase 3 AMPOWER study evaluating Phexxi™ for the prevention of pregnancy were published in Contraception: X. The study found that Phexxi™, a novel vaginal pH regulator, demonstrated 86.3% contraceptive effectiveness, was safe and well tolerated, and was highly acceptable. These findings represent a major contribution to women’s health, with the forthcoming availability of a new, non-hormonal, woman-controlled method of contraception that expands women's prevention options.
Thomas, M.; Chappell, B.T.; Maximos, B.; Cullwell, K.; & Howard, B.